Clinical trials: Injector
Plaque Psoriasis
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.
- Trial name
- UNCOVER-A (NCT01777191)
- Testing
- Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).
- Trial name
- NCT01879319
- Testing
- Evolocumab AMD, Evolocumab AI/pen
- Where
- 27 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Amgen
Rheumatoid Arthritis
An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis
An open-label, single arm study to estimate the rate of failure of the Enbrel® SureClick™ Auto-injector in RA subjects.
- Trial name
- NCT00346294
- Testing
- Etanercept
- Volunteers
- 115 people
- Sponsor
- Amgen
Hepatitis C, Opioid Use
The Staying Safe Intervention
The growing population of young people who inject drugs (PWID) is at extremely high risk for HCV infection through the use of contaminated injection equipment, yet, to date, no behavioral intervention has been sufficiently potent…
- Trial name
- Ssafe (NCT03418636)
- Testing
- Staying Safe (Ssafe), Healthy Living
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- National Development and Research Institutes, Inc.
Diabetes
Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose
In this study, QS-M needle-free injector and needle-insulin pen were used as a drug carrier to control blood glucose in type 2 diabetic patients（T2DM）.The efficacy and safety of QS-M needle-free injector and needle-insulin pen…
- Trial name
- NCT03243903
- Testing
- QS-M insulin-free injector, conventional insulin pen
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Beijing QS Medical Technology Co., Ltd.
Arthritis, Rheumatoid
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
The primary objective of the study is to compare, in patients treated with methotrexate injection for rheumatoid arthritis, the compliance and the health assessment questionnaire evolution for the administration by auto-injector…
- Trial name
- Self-i (NCT02553018)
- Testing
- Methotrexate
- Where
- 2 sites in France
- Volunteers
- 278 people
- Sponsor
- Nordic Pharma SAS
Rheumatoid Arthritis (RA)
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
The purpose of this study is to assess the usability of the VIBEX MTX device for SC self-injection of methotrexate.
- Trial name
- NCT01618955
- Testing
- VIBEX MTX
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Antares Pharma Inc.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection…
- Trial name
- NCT03766685
- Testing
- Bimekizumab
- Where
- 39 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- UCB Biopharma SRL
Asthma
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
Mepolizumab (SB-240563) is a humanized monoclonal antibody (Immunoglobulin G1, kappa, mAb) that blocks human interleukin-5 (hIL-5) from binding to the interleukin (IL)-5 receptor complex expressed on the eosinophil cell surface…
- Trial name
- NCT03014674
- Testing
- Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Response to DTP-HB-Hib Vaccine
Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants
This is a study planned to determine and compare immunogenicity and reactogenicity of DTP-HB-Hib vaccine of SIIL delivered either with disposable-Syringe Jet Injector (DSJI) or disposable-syringe needle in total 340 Indian…
- Trial name
- NCT02409095
- Testing
- DTP-HB-Hib vaccine, Disposable Syringe Jet Injector (DSJI), Needle & Syringe
- Where
- 3 sites in India
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®
- Trial name
- NCT02937766
- Testing
- Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Cataract
Clinical Outcomes After Implantation of a Monofocal Hydrophobic IOL, Bi-Flex 877PAY With POB-MA Preloaded Injector
The purpose of our investigation is to retrospectively assess visual outcomes, refractive stability, safety features of the lens and the incidence of developing PCO (posterior capsular opacification) in a 12-month period…
- Trial name
- NCT06469541
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Medicontur Medical Engineering Ltd
Diabetes, Diabetes Mellitus, Type 1
A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®
This trial is conducted in Europe. The aim of this trial is to compare Injections with the Medical Device DV3316 Pen-injector versus FlexPen®.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02627287
- Testing
- FlexPen®, DV3316 pen-injector
- Where
- 2 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Anesthesia
Jet Injectors Versus Conventional Anesthetic Technique in Children
This clinical study was conducted to compare the needleless Comfort-in jet injector device and the conventional needle technique in terms of 1. Pain level during the administration of local anesthesia in children. 2.
- Trial name
- NCT06314984
- Testing
- Group I A (Conventional needle syringe), Group I B (Conventional needle syringe), Group II A (Comfort-in Jet Injector)
- Where
- Egypt
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Hepatitis C, Chronic
A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3
This sudy will determine whether shortening treatment for hepatitis C is feasible, safe and effective for patients who are current injection drug users or receiving opiate substitution therapy and who are responding well to…
- Trial name
- ACTIVATE (NCT01364090)
- Testing
- Pegylated interferon alfa 2b, Ribavirin
- Where
- 17 sites in Australia, Belgium and 5 more
- Volunteers
- 93 people
- Sponsor
- Kirby Institute
Cataract, Lens Implantation, Intraocular
Comparative Clinical Study of Intraocular Lens Injectors Lioli™, Pioli™, and Pioli™ Plus
The goal of this observational study is to evaluate whether different intraocular lens (IOL) injectors affect surgical outcomes in patients aged 40 and older undergoing cataract surgery.
- Trial name
- NCT07140029
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- AST Products, Inc.
Migraine
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack.
- Trial name
- NCT00510419
- Testing
- "Investigational"Auto-injector (sumatriptan succinate)
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Pfizer
Healthy Subjects
Autoinjector Device Assessment Study
Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
- Trial name
- BCB119 (NCT02349802)
- Testing
- Auto-injector with exenatide suspension, Syringe with exenatide suspension
- Where
- 2 sites in United States
- Volunteers
- 3,052 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab…
- Trial name
- NCT06741657
- Testing
- Litifilimab, AI, OBI
- Where
- 2 sites in United States
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Biogen
Psoriatic Arthritis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after…
- Trial name
- NCT04109976
- Testing
- Bimekizumab
- Where
- 47 sites in United States, Czechia and 4 more
- Volunteers
- 214 people
- Sponsor
- UCB Biopharma SRL